Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.
Today in one sentence: People with lung cancer lived longer with immune-therapy plus chemo before surgery; early cervical cancer patients did well with a gentler node-check surgery; long-term data show gene therapy stays safe for a rare immune disease; a lupus drug (telitacicept) worked in a big trial; and donor insulin cells survived in people without immune-suppressing medicine.
Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8
Weekly personal shares from Christin here →
http://christin.substack.com/
Good news: This confirms people with lung cancer live longer with a treatment that’s already on the market.
Market readiness: 🙂🙂🙂🙂🙂 (approved regimen in the US; this is new 5-year survival data that reinforces current practice)
Good news: A less invasive surgery for early cervical cancer can spare patients complications without hurting survival.
Market readiness: 🙂🙂🙂🙂 (phase 3 RCT with survival outcomes; can be adopted quickly as guidelines update)
Good news: Gene therapy for a deadly immune-system disease continues to look safe and effective years later.
Market readiness: 🙂🙂🙂🙂 (clinically used in specialized centers; strong long-term data supports broader access)
Good news: A new antibody fusion therapy helped more people with lupus reach low disease activity in a large trial.
Market readiness: 🙂🙂🙂 (positive phase 3; not yet FDA-approved in the US)
Good news: Donor insulin-making cells survived in people with type 1 diabetes without immune-suppressing drugs.
Market readiness: 🙂🙂 (early clinical study using implant/device strategies; promising but still early)
Thank you for taking the time to take care of yourself and your loved ones.
